¿Cómo se compara el ratio PS de CYC con empresas similares?

CYC es un buen valor basado en su ratio Price-To-Sales (6.3x) comparado con la media de empresas similares (14.4x).

¿Cómo se compara el ratio PS de CYC con el de otras empresas de la industria AU Medical Equipment ?

CYC es cara en función de su ratio Price-To-Sales (6.3x) en comparación con la media de la industria Australian Medical Equipment (3.1x).

¿Cuál es el ratio PS de CYC comparado con su ratio PS justo? Este es el ratio PS esperado teniendo en cuenta las estimaciones de crecimiento de ingresos de la empresa, los márgenes de beneficios y otros factores de riesgo.

CYC es un buen valor basado en su ratio Price-To-Sales (6.3x) comparado con el ratio justo estimado Price-To-Sales (8.4x).

¿Cuál es el precio justo de CYC si consideramos sus flujos de caja futuros? Para esta estimación utilizamos un modelo de flujo de caja descontado.

CYC (A$1.37) cotiza por debajo de nuestra estimación de [[valor justo]] (A$11.57)

¿Cuál es la estimación de los analistas a 12 meses y, existe una confianza estadística en el precio objetivo de consenso?

Datos insuficientes para mostrar el pronóstico de precios.

Cyclopharm (ASX:CYC) - Cotización, noticias y análisis

Resumen de acción CYC

Cyclopharm Limited fabrica y vende equipos médicos y radiofármacos en Asia-Pacífico, Europa, Canadá y a escala internacional. Saber más

Análisis fundamental de CYC
Puntuación del snowflake
Valoración	4/6
Crecimiento futuro	5/6
Rendimiento pasado	0/6
Salud financiera	5/6
Dividendos	0/6

Recompensas

Cotiza un 88.2% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 104.88%

Análisis de riesgos

No tiene una capitalización de mercado significativa (A$152M)

Los accionistas han sido diluidos en el último año

Competidores de Cyclopharm Limited

Optiscan Imaging

ASX:OIL

AU$133.7m

ImpediMed

ASX:IPD

AU$109.3m

Austco Healthcare

ASX:AHC

AU$87.4m

SomnoMed

ASX:SOM

AU$52.9m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Cyclopharm
Precios históricos de las acciones
Precio actual de la acción	AU$1.37
Máximo en las últimas 52 semanas	AU$2.15
Mínimo de 52 semanas	AU$1.33
Beta	0.72
1Cambio en 1 mes	-13.02%
Variación en 3 meses	-2.49%
Cambio de 1 año	-33.17%
3Variación en 3 años	-28.83%
Variación en 5 años	19.13%
Variación desde la OPV	-26.93%

Noticias y actualizaciones recientes

Recent updates

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Oct 28

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Mar 02

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Oct 22

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Jun 29

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Apr 27

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Mar 01

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Feb 07

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

Jan 02

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Dec 06

Rentabilidad de los accionistas

	CYC	AU Medical Equipment	Mercado AU
7D	-0.7%	0.5%	1.5%
1Y	-33.2%	14.2%	17.2%

Rentabilidad vs. Industria: Los resultados de CYC fueron inferiores a los de la industria Australian Medical Equipment, que obtuvo un rendimiento del 14.2% el año pasado.

Rentabilidad vs. Mercado: CYC obtuvo unos resultados inferiores a los del mercado Australian, que fueron del 17.2% el año pasado.

Volatilidad de los precios

Is CYC's price volatile compared to industry and market?
CYC volatility
CYC Average Weekly Movement	6.4%
Medical Equipment Industry Average Movement	9.1%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Precio estable de las acciones: CYC no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CYC (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1986	87	James McBrayer	www.cyclopharm.com

Cyclopharm Limited fabrica y vende equipos médicos y radiofármacos en Asia-Pacífico, Europa, Canadá y a escala internacional. La empresa opera a través de los segmentos Technegas y Molecular Imaging. El segmento Technegas ofrece equipos de diagnóstico y consumibles utilizados por los médicos en la detección de la embolia pulmonar.

Resumen de fundamentos de Cyclopharm Limited

¿Cómo se comparan los beneficios e ingresos de Cyclopharm con su capitalización de mercado?
Estadísticas fundamentales de CYC
Capitalización bursátil	AU$152.26m
Beneficios(TTM)	-AU$9.32m
Ingresos (TTM)	AU$24.06m

6.3x

Ratio precio-ventas (PS)

-16.3x

Ratio precio-beneficio (PE)

¿Está CYC sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CYC
Ingresos	AU$24.06m
Coste de los ingresos	AU$10.23m
Beneficio bruto	AU$13.82m
Otros gastos	AU$23.14m
Beneficios	-AU$9.32m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.084
Margen bruto	57.47%
Margen de beneficio neto	-38.72%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado CYC a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción CYC

Recompensas

Análisis de riesgos

Competidores de Cyclopharm Limited

ASX:OIL

AU$133.7m

ASX:IPD

AU$109.3m

ASX:AHC

AU$87.4m

ASX:SOM

AU$52.9m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New minor risk - Market cap size

Non-Executive Director recently bought AU$51k worth of stock

Consensus revenue estimates fall by 13%

First half 2024 earnings released: AU$0.078 loss per share (vs AU$0.032 loss in 1H 2023)

Forecast breakeven date pushed back to 2026

New minor risk - Shareholder dilution

Recent updates

New minor risk - Market cap size

Non-Executive Director recently bought AU$51k worth of stock

Consensus revenue estimates fall by 13%

First half 2024 earnings released: AU$0.078 loss per share (vs AU$0.032 loss in 1H 2023)

Forecast breakeven date pushed back to 2026

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Market cap size

Consensus revenue estimates fall by 14%

Cyclopharm Limited, Annual General Meeting, May 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director

Consensus EPS estimates fall by 11%

CEO, MD exercised options to buy AU$402k worth of stock.

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: AU$0.032 loss per share (vs AU$0.028 loss in 1H 2022)

Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023

Consensus estimates of losses per share improve by 13%

Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Consensus EPS estimates fall by 153%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023

Less than half of directors are independent

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Less than half of directors are independent

Cyclopharm Limited Appoints Gregory King as A Non-Executive Director

Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director

First half 2022 earnings released: AU$0.028 loss per share (vs AU$0.045 loss in 1H 2021)

Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022

Consensus revenue estimates increase by 10%

Cyclopharm Limited Announces Independent Multicentre Study Highlights the Benefits of Technegas in Diagnosing Pulmonary Embolism in Growing Covid-19 Patient Population

Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Cyclopharm Limited Announces Technegas Used in Diagnosing Long COVID

Full year 2021 earnings: Revenues exceed analyst expectations

Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Consensus revenue estimates increase by 14%

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022

Cyclopharm Limited Provides Earnings Guidance for the Full Year 2021

Less than half of directors are independent

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.045 loss per share (vs AU$0.074 loss in 1H 2020)

Cyclopharm Limited Provides Unaudited Revenue Guidance for the First Half of 2021

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Consensus revenue estimates fall to AU$16.5m

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Cyclopharm Limited provides Confirmation of Technegas USFDA Timetable

Analysts increase revenue estimates to AU$18.6m

Cyclopharm Limited, Annual General Meeting, May 04, 2021

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Revenue beats expectations, earnings disappoint